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The detection of atherosclerosis has changed considerably
over the past few decades, with an ever-increasing array of
diagnostic tools available to the researcher and practicing
clinician. For many decades, traditional risk factor assess-
ment was the mainstay for prognostication, forming a basis
for preventive strategies aimed at risk reduction. More
recently, new laboratory markers (e.g., C-reactive protein),
as well as cardiac imaging techniques (e.g., electron beam
computed tomography [EBCT]), are being advocated as
optimal tools for the detection of subclinical disease and as
predictors of obstructive coronary artery disease (CAD) and
worsening prognosis. Electron beam computed tomography
is attractive due to the ease of measurement of coronary
calcium as compared with other measures, such as carotid
intimal medial thickness. Considerable previous evidence
suggests that the extent of coronary calcification is strongly
related to plaque burden, but is less reliable for detecting
vulnerable plaque (1,2). Calcification of the coronary artery
occurs as part of the development of atherosclerosis and is
not present in a normal vessel wall. As an emerging
technique, EBCT has merit but also disadvantages that
temper our enthusiasm for its widespread clinical use (2).
Recently, the American College of Cardiology in associ-
ation with the American Heart Association (AHA) pre-
sented an updated technology evaluation on the use of
EBCT for the diagnosis of CAD in symptomatic patients,
for risk assessment in asymptomatic individuals and for
serial monitoring of drug therapy (2,3). Other reviews on
EBCT have been published by the AHA Prevention V
Conference and Blue Cross/Blue Shield Technology Eval-
uation Center (Chicago, Illinois). From either the payer
perspective or that of medical societies, there is consensus
that widespread use of EBCT for disease or risk assessment
is not supported by current data (2,3). When examining the
predictive accuracy of EBCT, the weight and quality of the
evidence are dependent on the rigor with which the data are
analyzed, as well as its comparative accuracy in relation to
other noninvasive techniques (2). This editorial comment
highlights the current state of evidence on EBCT, including
examples from the Arad report (4) in this issue of the
Journal.
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In our cost-conscious era, new technology, such as EBCT
or echocardiographic contrast agents, must now provide a
sufficiently high level of scientific evidence before accep-
tance and assimilation into daily clinical practice. Health
care payers and other group health organizations also
require evidence of favorable outcomes and specific clinical
pathways as part of the contractual process for new tech-
nology. European drug/device approval agencies and many
western European countries are considering the requirement
of long-term clinical outcome and cost-effectiveness data
before approval and use of any new drug or device. Al-
though these are new standards for diagnostic tests, thera-
peutic agents have long been held to the benchmark of
well-designed, statistically powered, controlled clinical ob-
servations that are rigorously analyzed. Only recently have
outcomes data on noninvasive testing of more than 1,000
patients been published (5,6).
Challenges of event prediction with EBCT coronary
calcium scores. A major benefit of EBCT would be the
improved detection of subclinical disease in asymptomatic
individuals (2–4). Detection of high risk subsets from
asymptomatic cohorts was the focus of the current report by
Arad et al. (4) and in a related series from the South Bay
Heart Watch Program (4,7). Imaging of atherosclerotic
plaque has been done by many techniques, including mag-
netic resonance imaging and positron emission tomographic
imaging. For EBCT, calcification of the coronary arteries
provides an additional method to assess plaque burden.
From the St. Francis Medical Center and the South Bay
Heart Watch Program (4,7), the prognostic value of EBCT
was reported using an array of combined end points,
including cardiac death (an infrequent event in low risk
groups), acute coronary syndromes and coronary revascular-
ization. Although combined end points are often used in
small patient samples (e.g., n 5 1,172) (4), factors contrib-
uting to cardiac mortality differ from those of nonfatal
myocardial infarction and other coronary events. In general,
the amount of coronary calcium estimates a small percent-
age of the total plaque burden, with most atherosclerotic
lesions not being calcified (1,2,7). Rupture of vulnerable
plaque is associated with the occurrence of acute coronary
syndromes. Event prediction, including sudden cardiac
death or acute coronary thrombosis, more often occurs in
lesions with vulnerable plaque but less extensive coronary
calcification (8,9). The low positive predictive value of
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coronary calcium in the current series is expected. The
resulting usefulness of EBCT may be problematic in low
risk groups in which the majority of events are acute
myocardial infarction (i.e., in Arad et al. [4], 15 of 18 events
were nonfatal infarction) (4).
Moreover, the use of coronary revascularization as an end
point is suspect because of its subjective nature, as well as
any influence calcium scores exert on post-test management.
In the Arad study, only symptom-driven revascularization
was considered. Despite this, incremental models are pre-
ferred, including an initial prognostic model estimating
“hard” events (i.e., death and/or myocardial infarction),
followed by models assessing combined events. This would
also foster comparisons with other published predictive
models of death or infarction. There should also be a
disjointing between revascularization occurring early (i.e.,
within 90 days) and late after testing. Late revascularization
reflects clinical worsening and is acceptable as a clinical
outcome (10).
Although there may be some association between coro-
nary calcium and many clinical outcomes, its major strength
may be in predictive models that estimate the presence or
extent of the underlying atherosclerotic disease burden. It is
likely that the optimal outcome model using coronary
calcium, as a surrogate for total plaque burden, may be the
development of symptomatic coronary heart disease (ex-
cluding unstable anginal symptoms). These models, as yet
untested, mirror the development of risk factor equations
from the Framingham Heart Study (11–13).
In the Arad report, coronary calcium scores .80, .160
and .600 were independent predictors of combined events,
with the adjusted odds ratio ranging from 14.3- to 20.2-fold
higher (4). Comparison of the EBCT odds ratio with other
published odds ratios (e.g., cholesterol levels) should be
viewed with extreme caution, because variation is driven by
sample size, outcome frequency and modeling strategies.
For patients with an elevated calcium score, the odds ratio is
defined as some X-fold increase in event risk over that of
patients with a lower calcium score. However, this risk ratio
is not independent of the underlying risk in the patient
group. In an exceedingly low risk group, such as the Arad
series, the odds ratio for a high calcium score may be
elevated 14.3-fold, with the actual event rate remaining low
risk at 0.8%; as such, odds ratios require insight into the
observed event rate for interpretation. The current report
lacks much of the prognostic detail that would provide
enhanced insight into the value of EBCT.
Epidemiologic principles garnered over the last several
decades on estimating prognosis may guide the evaluation of
EBCT as a tool for risk stratifying groups (10,14). Historic,
physical examination and laboratory variables form the basis
for initial risk assessment and additional test selection (11).
Previous research on population screening favors use of
measured risk factors (2,3,11). In a diagnostic testing
environment (e.g., exercise electrocardiography), a physi-
cian’s interview often supplants direct risk factor measure-
ment. Generally, a physician’s interview would be biased
toward underestimating the value of historic markers (in lieu
of supplemental imaging data). Variation in total informa-
tion content for risk prediction is expected between directly
measured and historic risk factors (4,7). If EBCT is to be
used as a screening tool for primary prevention, then its
added value must exceed information obtained from low
cost laboratory variables such as blood glucose or cholesterol
levels. Recently, Taylor et al. (15) suggested that coronary
calcium may provide complementary information in relation
to Framingham risk profiles. If this is so, then quantifying
the additive relation is necessary to focus clinical decision-
making including EBCT.
The current series includes asymptomatic subjects who
were self- or physician-referred for screening with EBCT
(4). The challenges with screening asymptomatic individu-
als are that the life-time risk of CAD is appreciable and,
despite having low event rates, ;50% of all sudden cardiac
deaths and acute myocardial infarctions occur in asymptom-
atic people (16). Provocative testing has demonstrated
limitations when applied to screening of asymptomatic
cohorts (17). Previous reports, such as the Lipid Research
Clinic prevention trial (18), noted that a positive test was
not associated with nonfatal myocardial infarction or that,
such as in the Seattle Heart Watch study, an abnormal ST
segment response during exercise was not associated with an
increased risk of cardiac events (19). Limitations to testing
asymptomatic subjects relate to a lower disease prevalence
and apply to any diagnostic modality, including EBCT. The
application of Bayes’ theorem may provide us with insight
into the precision of risk assessment in low risk groups.
Bayes’ theorem states that the probability of a positive test
being truly positive (i.e., underlying disease is present)
relates to the prevalence of disease in the screened popula-
tion (17). When clinical risk is low, an abnormal test will
not result in a substantial reclassification in risk, due to a
minimal shift in post-test probabilities. These results have
direct relevance to EBCT data derived from low risk cohorts
where high misclassification rates (i.e., false negative/
positive tests) are expected.
Recent clinical guidelines have identified risk cut-points
that may guide the interpretation of the data of Arad et al.
(4,20). The annualized cardiac death or myocardial infarc-
tion rate from their study was 0.4%—a decidedly low risk
cohort (defined as annual risk ,1%) (4,20). Annualized
event rates were substantially higher in the report by
Detrano et al. (7). A continuum of risk is expected through
the spectrum of disease states, ranging from asymptomatic
without and then with risk factors, and finally to even higher
risk symptomatic outpatient groups (5). Variations in the
predictive value of EBCT would be expected in groups with
varying underlying risk profiles.
Risk-adjusted odds ratios for calcium scores $160 were
elevated 19.7-fold. It is expected that this threshold would
be associated with death or infarction rates of ;4%—not
unlike multivessel perfusion abnormalities or left ventricular
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dysfunction as demonstrated by other cardiac imaging
procedures (4,20). Aggressive management of these high
risk patients would be warranted (20). However, from the
Arad report, the 75th percentile calcium score was 97—
approaching their threshold score of 160 (4). The challenge
of testing low risk groups is that, based on these data, ;25%
of the group (n 5 293) would be identified as EBCT high
risk (4). Thus, treatment would be recommended for a
sizable proportion of individuals, with only one of five
people receiving therapeutic benefit from the intervention.
A further challenge to this cut-point is that the average
score of patients without events was 135, with a wide
standard deviation of 432. The goal of risk stratification
should be to limit aggressive and costly care to a select group
of high risk patients (5,6). From this series, the total cost to
identify one event using EBCT would exceed $3,200 (21).
Evaluating current evidence: statistical and epidemio-
logic issues. Major challenges to the interpretation of
EBCT data include a number of methodologic problems,
including small sample size, failure to use appropriate
survival analysis techniques, lack of standard covariate ad-
justment and other variations in data collection methods
(10,12,14). Considering the recent introduction of EBCT,
one would not expect a large amount of effectiveness data to
be available. Standards for new technology include the
development of published evidence where the estimation of
patient outcomes must be established in sufficiently large
patient samples, with the data rigorously collected and
analyzed from a diverse array of patient subsets.
Simple risk assessment statistics include the positive (i.e.,
total number of events/number of patients with abnormal
test results) and negative (i.e., total number of nonevents/
number of patients with normal test results) predictive value
of a risk marker. Standard measures to test diagnostic
accuracy are sensitivity (defined as true positive test results/
number of patients with disease) and specificity (defined as
true negative test results/number of patients without dis-
ease). In the current report, the use of sensitivity and
specificity measures varies from previous risk stratification
reports (12). Despite this, the best predictive accuracy
achieved in the receiver operating characteristics (ROC)
curve of myocardial infarction or coronary death was
achieved at a square root calcium score of 15, with sensi-
tivity and specificity of ;80% (4).
For prognostic analysis, standard assessments of risk
include the use of a Cox proportional hazards model. As
events occur over time, this analytic method calculates
time-related variation in the occurrence of events based on
a given predictive model. Two types of models are com-
monly used: unadjusted and adjusted equations. For an
unadjusted model, EBCT coronary calcium scores would
provide enhanced or equivalent outcome estimation as
compared with cardiac risk factors or laboratory variables. A
critical step in the assessment of prognosis is the use of
risk-adjusted outcome models, where the prognostic signif-
icance of EBCT is assessed while controlling or adjusting
for pretest information (including clinical history, physical
examination and laboratory markers). The amount of added
information could then be statistically quantified in relation
to the estimation of cardiac events. This incremental value
may be used to justify the added cost of this procedure. A
10% to 20% added value of stress testing (with and without
imaging) in symptomatic patients for risk assessment pur-
poses was reported (5,6). In the current report from the St.
Francis Medical Center, unadjusted and adjusted logistic
regression analyses were used (4).
The authors further explore the accuracy of EBCT
coronary calcium scores using ROC curves (4). Tradition-
ally, ROC curves are used for diagnostic models, whereas in
the Cox model, a concordance (C-) index is used that
reflects the ability of a model to correctly classify patients
with and without events (10,14). A C-index near chance
would be at ;0.5, and perfect estimation would be 1.0. The
ROC curves areas exceeded 0.80 in the Arad series (4).
From the current ROC curves, the square root coronary
calcium score proved to be a highly specific tool for the
estimation of myocardial infarction or cardiac death, at a
substantial loss in sensitivity, reflecting a high false negative
rate (4). With false negative rates being a surrogate for cost
waste, the induced downstream medical resource consump-
tion from EBCT would be excessive. Optimization of ROC
curves may be accomplished by partitioning the curve to
optimize sensitivity and specificity measures. For EBCT,
cost waste infers an inability to identify a truly low and high
risk subset of the population. A more balanced predictive
accuracy may be achieved in larger samples than that of the
Arad series (n 5 1,172). Furthermore, given the current
sample, there is insufficient statistical power to detect
outcome differences in this low risk group. Given a 1%
difference in event rates, sample size estimates could ap-
proach 5,000 subjects to detect differences by calcium score
subsets.
Building effectiveness data in a cost-conscious environ-
ment. One reason for the lack of support for the use of
EBCT has been related to a new standard for medical
evidence that is increasingly applied in a cost-conscious
health care environment. Added value of a test to the
clinician and consumer is determined by the amount of new
prognostic or diagnostic data that are derived from each
comparative test in relation to its production cost, as well as
any induced costs. Historically, new medical technology is
associated with an increase in medical service use and added
resource intensity. Increasingly, health care payers have
introduced new standards beyond initial efficacy data that
provide clinical effectiveness data for patient management.
Data by Arad et al. (4) provide us with insight into the
current prognostic data that are available with EBCT, but
call for the development of larger series established in
heterogeneous patient subsets. In addition to the develop-
ment of a large registry by the Society for Atherosclerotic
Imaging, the National Institutes of Health is embarking on
a multi-institution study (Multiethnic Study of Atheroscle-
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rosis) evaluating the ability of EBCT and other methods
(e.g., ankle-brachial index and magnetic resonance imaging)
to identify high risk subsets.
For low risk groups, many have argued that the cost to
identify so few events far exceeds society’s willingness to
pay, and, perhaps, our limited resources may be better
allocated to areas of greater need. Evidence suggests that
treating low risk patients is not cost effective as compared
with treating higher risk groups (i.e., high risk cost-
effectiveness model) (22). Screening for CAD in asymptom-
atic individuals is difficult owing to the infrequent event
incidence and to the exaggerated costs of identifying rare
outcomes. Using routine screening, Pilote et al. (23) recently
explored the clinical yield of exercise testing in 4,334
asymptomatic subjects. The rate of positive tests was 15%,
whereas the angiographic CAD rate was 0.4%. As a
consequence, screening costs were excessive in relation to
the amount of CAD detected and resulted in additional
unnecessary testing (24).
Despite the interest on the part of the cardiology com-
munity for new diagnostic tools to detect preclinical CAD,
current data are inadequate to support the use of EBCT. As
a risk assessment test, EBCT is more costly than other types
of testing, while currently providing less abundant evidence
to justify its use. Because this test is being actively marketed
to and used by the American public, the current weight of
evidence suggests that it should be performed in selected
groups, with the result being a more judicious use of this
procedure. Moreover, a more rigorous approach to the
evaluation of EBCT would require a randomized trial
comparing this technology with comparative modalities for
a definitive evaluation. As direct marketing to consumers
has become a mainstay in our society, the medical commu-
nity must increasingly set standards in the best interest of
our patients and society, advocating clinically effective and
cost-effective use of any medical procedure, including
EBCT. We await a greater compendium of data to provide
support for the additive prognostic value of EBCT in
asymptomatic individuals.
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